Drug Name Dosages Therapeutic Indications Adverse Contraindicati Nursing

Actions effects ons Responsibilities

Generic Drug: PO Betamethaso Systemic Sodium and Hypersensitivi Assessment
Betamethasone Allergic and ne is a administration fluid ty; systemic
inflammatory corticosteroi retention, fungal or  History
Brand Name: disorders; d with mainly  Hypercal potassium acute (Systemic
Celestone, congenital glucocorticoi cemia and calcium infections administration):
Celestone adrenal d activity. It associate depletion. Infections, fungal
Soluspan, hyperplasia prevents and d with Muscle infections,
Betaject, 0.5-5mg/day. by controlling cancer wasting, amebiasis, vaccinia
Betamethasone IM the rate of  Short- weakness, and varicella, and
IM/PO Allergic and protein term osteoporosi antibiotic-resistant
inflammatory synthesis, manage s.GI infections; kidney
Classification: disorders as depressing ment of disturbance or liver disease;
Corticosteroids betamethasone the migration inflamm s and hypothyroidism;
Na phosphate of atory bleeding. ulcerative colitis
and polymorphon and Increased with impending
betamethasone uclear allergic appetite perforation;
acetate: leukocytes disorders and delayed diverticulitis; active
Initial:0.25-9 and , such as wound or latent peptic
mg/day in1-2 fibroblasts, rheumat healing; ulcer;
divided doses. and reversing oid hirsutism, inflammatory
Ophth Allergic capillary arthritis, bruising, bowel disease;
and permeability collagen striae, acne; CHF; hypertension;
inflammatory and diseases raised thromboembolic
conditions of lysosomal (eg, SLE), intracranial disorders;
the eye as 0.1% stabilization. dermatol pressure, osteoporosis;
soln: As Na ogic headache, seizure disorders;
phosphate: diseases depression, diabetes mellitus;
Instill 1-2 hrly (eg, psychosis, lactation
until symptoms pemphig menstrual
are controlled. us), irregularitie  Physical:
As0.1% oint: status s. Baseline weight, T,
As Na asthmati Hyperglyce reflexes and grip
phosphate: cus, and mia, strength, affect
Apply2-4 autoimm DM. and orientation, P,
times/day or at une Suppression BP, peripheral
night w/ the disorders of pituitary- perfusion,
eyedrops. adrenocorti prominence of
Topical Skin  Hematol cal axis. superficial veins,
disorders As ogic Growth Rand adventitious
dipropionate retardation
(0.05%) or disorders in children sounds, serum
valerate (0.025 : (prolonged electrolytes, blood
or 0.1%): Apply Thrombo therapy). glucose
as directed cytopeni Increased
a susceptibilit Interventions
purpura, y for
erythrobl infections. Systematic use
astopeni Topical use:
a Dermal  Give daily
atrophy, dose 9am
 Ulcerativ local to mimic
e colitis, irritation, normal
acute folliculitis, peak
exacerba hypertricho corticoste
tions of sis. roid blood
MS, and Inhalation: levels.
palliation Hoarseness,  Increase
in some candidiasis dosage
leukemia of mouth when
s and and patient is
lympho throat. subject to
mas Topical stress
application  Taper
 Trichinos to the eye: doses
is with Corneal when
neurolog ulcers, discontinu
ic or raised IOP ing high
myocardi and reduced dose or
al visual long-term
involvem acuity. therapy
ent Intradermal
 Do not
injection:
give live
Local
virus
hypopigmen
vaccines
tation of
with
deeply
immunos
pigmented
uppressiv
skin. Intra-
e doses of
articular
corticoste
injection:
roids.
Joint
damage,
Topical
fibrosis, esp.
dermatologic
in load
preparations
bearing
joints
Examine area for
infections and
skin integrity
before application

 Administ
er
cautiousl
y to
pregnant
patients’
topical
corticost
eroids
have
caused
teratoge
nic
effects
and can
be
absorbed
from
systemic
site.